My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 152

    1.

    Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study.

    Topol EJ, Bell WR, Weisfeldt ML.

    Ann Intern Med. 1985 Dec;103(6 ( Pt 1)):837-43.PMID: 3933395 [PubMed - indexed for MEDLINE]Related articles

    2.

    Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.

    Mueller HS, Rao AK, Forman SA.

    J Am Coll Cardiol. 1987 Sep;10(3):479-90.PMID: 3114349 [PubMed - indexed for MEDLINE]Related articles

    3.

    Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group.

    Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Anderson L, Collen D.

    Circulation. 1989 Nov;80(5):1222-30.PMID: 2509104 [PubMed - indexed for MEDLINE]Related articles

    4.

    Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.

    Collen D, Bounameaux H, De Cock F, Lijnen HR, Verstraete M.

    Circulation. 1986 Mar;73(3):511-7.PMID: 2419009 [PubMed - indexed for MEDLINE]Related articles

    5.

    Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction.

    Stangl K, Laule M, Tenckhoff B, Stangl V, Gliech V, Dübel P, Grohmann A, Melzer C, Langel J, Wernecke KD, Baumann G, Ziemer S.

    Am J Cardiol. 1998 Apr 1;81(7):841-7.PMID: 9555772 [PubMed - indexed for MEDLINE]Related articles

    6.

    A randomised dose ranging study of recombinant tissue plasminogen activator in acute myocardial infarction.

    McNeill AJ, Shannon JS, Cunningham SR, Flannery DJ, Campbell NP, Khan MM, Patterson GC, Webb SW, Adgey AA.

    Br Med J (Clin Res Ed). 1988 Jun 25;296(6639):1768-71.PMID: 3136831 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator]

    Verstraete M, Bory M, Collen D, Erbel R, Lennane RJ, Mathey D, Michels HR, Schartl M, Uebis R, Bernard R, et al.

    Klin Wochenschr. 1988;66 Suppl 12:77-85. German. PMID: 3126348 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of lipoprotein(a) on thrombolysis.

    von Hodenberg E, Pestel E, Kreuzer J, Freitag M, Bode C.

    Chem Phys Lipids. 1994 Jan;67-68:381-5.PMID: 8187238 [PubMed - indexed for MEDLINE]Related articles

    9.

    Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group.

    Zeymer U, von Essen R, Tebbe U, Niederer W, Mäurer W, Vogt A, Neuhaus KL.

    Am J Cardiol. 1995 Nov 15;76(14):997-1001.PMID: 7484879 [PubMed - indexed for MEDLINE]Related articles

    10.

    Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency.

    Cowley MJ, Hastillo A, Vetrovec GW, Fisher LM, Garrett R, Hess ML.

    Circulation. 1983 May;67(5):1031-8.PMID: 6831667 [PubMed - indexed for MEDLINE]Related articles

    11.

    [Variations in hemostasis and fibrinolysis during the treatment of acute myocardial infarct (AMI) with tissue-type plasminogen activator (TTPA). A study of 17 cases]

    Izaguirre Avila R, Ruiz de Chávez Cervantes A, Villavicencio R, Gómez Trigos A, Mar Chavira R, Spíndola Mdel C, Casanova JM.

    Arch Inst Cardiol Mex. 1993 May-Jun;63(3):235-40. Spanish. PMID: 8347053 [PubMed - indexed for MEDLINE]Related articles

    12.

    Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.

    Eisenberg PR, Sobel BE, Jaffe AS.

    J Am Coll Cardiol. 1992 Apr;19(5):1065-9.PMID: 1552097 [PubMed - indexed for MEDLINE]Related articles

    13.

    A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.

    Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, et al.

    Circulation. 1995 Oct 15;92(8):2044-9.PMID: 7554180 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.

    Stump DC, Topol EJ, Chen AB, Hopkins A, Collen D.

    Thromb Haemost. 1988 Apr 8;59(2):133-7.PMID: 2455358 [PubMed - indexed for MEDLINE]Related articles

    15.

    Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.

    Verstraete M, Su CA, Tanswell P, Feuerer W, Collen D.

    Thromb Haemost. 1986 Aug 20;56(1):1-5.PMID: 3095944 [PubMed - indexed for MEDLINE]Related articles

    16.

    Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator.

    Gram J, Munkvad S, Leebeek FW, Kluft C, Jespersen J.

    Coron Artery Dis. 1993 Apr;4(4):371-7.PMID: 8261210 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency.

    Meierhenrich R, Carlsson J, Seifried E, Pfarr E, Smolarz A, Neuhaus KL, Tebbe U.

    Int J Cardiol. 1998 Jun 1;65(1):57-63.PMID: 9699932 [PubMed - indexed for MEDLINE]Related articles

    18.

    Thrombolytic therapy with recombinant human tissue-type plasminogen activator: a comparison of two doses.

    Risius B, Graor RA, Geisinger MA, Zelch MG, Lucas FV, Young JR.

    Radiology. 1987 Aug;164(2):465-8.PMID: 3110860 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    [A trial of the use of a new thrombolytic preparation--recombinant tissue-type plasminogen activator--in myocardial infarct patients]

    Plotnikov AN, Staroverov II, Tagieva IA, Dorogun BN, Pomerantsev EV, Dobrovol'skiĭ AB, Ruda MIa.

    Kardiologiia. 1993;33(3):32-6. Russian. PMID: 8377337 [PubMed - indexed for MEDLINE]Related articles

    20.

    Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator.

    Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Johns JA, Thornton D, Collen D.

    Thromb Res. 1988 Apr 1;50(1):121-33.PMID: 3135634 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity